ClinicalTrials.gg
CompletedNCT00806208Updated Dec 11, 2008

Trial for Evaluation of Safety of Escalating Dose Levels of MEDI-507 in Patients for Treatment of at Least Grade II Graft-Versus-Host Disease (GvHD)

A Phase 1 interventional study of MEDI-507 and MEDI-507 in Graft-Versus-Host Disease, sponsored by MedImmune LLC. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-12-11.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
174th of 389
34 · median 30
Started
1999
with 14 others
Phase 1
90 of 454
14 open now
Registered
179th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 174th largest by enrollment of the 389 interventional ones that give a count, is one of 15 that started in 1999, is one of 90 in phase 1, and was the 179th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

A trial to assess safety of four doses of MEDI 507 combined with another drug for initial treatment of at least Grade II acute Graft-vs-Host Disease in recipients.

Read the detailed description

The primary objective of this study is to assess safety of four dose levels of MEDI 507 combined with methylprednisolone for initial treatment of at least Grade II acute GvHD in stem cell or bone marrow allograft recipients.

03

Conditions studied

  • Graft-Versus-Host Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. allogeneic bone marrow or hematopoietic stem cell graft recipients
  2. acute GvHD of at least Grade II severity
  3. receipt of at least 2 mg/kg of methylprednisolone (or equivalent ) within eight to 24 hours prior to initial receipt of study drug
  4. evidence of engraftment (ANC over 1,000 cells/mm3)
  5. histologic evidence of GvHD from performed during the current episode
  6. receipt of GvHD prophylaxis of methotrexate, tacrolimus or cyclosporine
  7. age at least 18 years
  8. body weight under 130 kg
  9. Both males and females are eligible, but females of , unless previously surgically sterilized, agree to use an effective method of (e.g., abstinence, intrauterine contraceptive device, oral contraceptives, diaphragm or condom in combination with contraceptive jelly, cream or foam, Norplant7 or DepoProvera7) beginning with the first study injection and continuing through 60 days after the final study injection.

Exclusion criteria

Exclusion Criteria:

  1. previous receipt of MEDI 507
  2. diagnosis of chronic GvHD
  3. previous treatment with any anti-T-cell monoclonal antibodies such as OKT73 or daclizumab (Zenapax7)
  4. receipt of antithymocyte globulin (ATGAM7 or other ATG) within 14 days
  5. treatment with more than 0.3 mg/kg/day of methylprednisolone (or equivalent ) for more than 72 hours for the treatment of GvHD
  6. intolerance or history of intolerance to corticosteroids such that it is unlikely the patient will be able to complete at least ten days of corticosteroid therapy (2 mg/kg/day of methylprednisolone or equivalent)
  7. more than one allogeneic bone marrow or hematopoietic stem cell allograft
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Active comparator
    1

    MEDI 507 and Methylprednisolone

    Drug: MEDI-507

  • Active comparator
    2

    MEDI-507 and Methylprednisolone

    Drug: MEDI-507

  • Active comparator
    3

    MEDI-507 and Methylprednisolone

    Drug: MEDI-507

  • Active comparator
    4

    MEDI-507 and Methylprednisolone

    Drug: MEDI-507

  • Placebo comparator
    5

    Placebo

    Other: Placebo

Interventions

  • 0.012 mg/kg MEDI 507 and Methylprednisolone

  • 0.04 mg/kg MEDI 507 and Methylprednisolone

  • 0.12 mg/kg MEDI 507 and Methylprednisolone

  • 0.4 mg/kg MEDI 507 and Methylprednisolone

  • OtherPlacebo

    Placebo IV (alternative) study days 0, 3,6, and 9

06

What researchers measure

Primary outcomes

  1. Safety; first infusion of study drug

    Time frame: Through Study Day 44

07

Study locations

3 sites
  • Washington University Medical Center
    St. Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-7680, United States
  • Baylor Institute of Transplant Sciences
    Dallas, Texas 75246, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1999, a primary completion of Jan 2000 and a completion of Mar 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2008
First posted
Dec 10, 2008
Start
Jan 1999
Primary completionActual
Jan 2000
CompletionActual
Mar 2000
Last update
Dec 11, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00806208
Lead sponsor
MedImmune LLC
First posted
Dec 10, 2008
Start date
Jan 1999
Primary completion
Jan 2000
Completion
Mar 2000
Last update
Dec 11, 2008

Study contacts

J. Bruce McClain, M.D.
study director · MedImmune LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion